. . . . . "S&T TWOC Project - version 4" . "S&T TWOC version 3" . "2"^^ . "2023-07-20T09:47:17.075624"^^ . . . "for COVID-19 therapy" . "(368, 386)" . "considered" . "498" . "other antibiotics like azithromycin , ivermectin , eravacycline , valrubicin , streptomycin , nitazoxanide , teicoplanin , caspofungin , and colistin ; and other agents like hydroxychloroquine , chloroquine , tocilizumab , camostat , nafamostat , carfilzomib , interferon , aprepitant , and dexamethasone" . "(368, 386)" . "Results Repurposing of drugs from different pharmacological groups including antivirals like remdesivir, lopinavir, ritonavir, arbidol, oseltamivir, penciclovir, favipiravir, ganciclovir, and ribavirin; other antibiotics like azithromycin, ivermectin, eravacycline, valrubicin, streptomycin, nitazoxanide, teicoplanin, caspofungin, and colistin; and other agents like hydroxychloroquine, chloroquine, tocilizumab, camostat, nafamostat, carfilzomib, interferon, aprepitant, and dexamethasone can be considered for COVID-19 therapy." . "8j41d0a3" . "8j41d0a3-TRIPLE-ABSTRACT-2" . "hydroxychloroquine" . "therapy" . "RSA" . "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" . "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" . . .